CLAIMS:

1. A hyperstable liposome comprising an inner milieu separated from an external environment by a membrane, the inner milieu comprising an anti-mitotic drug, two anions and one or more cations entrapped in the inner milieu,

   wherein the anti-mitotic drug is a polo-like kinase inhibitor, a kinase spindle inhibitor or an aurora kinase inhibitor,

   wherein the membrane comprises l,2-distearoyl-sn-glycerol-3-phosphoethanolamine-N-[methoxy (polyethylene glycol)- 2000] (DSPE-PEG2000), hydrogenated egg L-α-phosphatidyl-choline (HEPC) and cholesterol (Chol), wherein the molar ratio of HEPC:Chol:DSPE-PEG2000 is 50:45:5,

   wherein the two anions are citrate and phosphate, citrate and acetate or acetate and phosphate in a ratio of 1:3 to 1:7, and

   wherein the entrapped anti-mitotic drug is released at a slow rate that is less than 0.6% in 12 hours or less than 5% in 8 days when the liposome is suspended in 600 mM sucrose.

2. The hyperstable liposome of claim 1, wherein the two anions are citrate and phosphate or citrate and acetate.

3. The hyperstable liposome of claim 1 or 2, wherein two anions are present in a ratio of 1:3 to 1:4.

4. The hyperstable liposome of claim 3, wherein the two anions are citrate and phosphate.

5. The hyperstable liposome of any one of claims 1-4, wherein the one or more cations are sodium, ammonium, triethylammonium, copper, magnesium, zinc or iron.

6. The hyperstable liposome of any one of claims 1-5, wherein the polo-like kinase inhibitor is BI2536, ON01910, GSK 461364, HMN 214 or BI 6727.

7. The hyperstable liposome of any one of claims 1-5, wherein the kinesin spindle inhibitor is Ispinesib (SB 715992), SB 743 921, MK 0731 or ARRY 520.

8. The hyperstable liposome of any one of claims 1-5, wherein the aurora kinase inhibitor is MK 0457 (VX 680), AZD 1152, PHA 680632, PHA 739358, MLN8054, MLN8237, R763, AT9283, SNS 314, SU 6668, ENMD 2076, BI 811283, CYC116, ENMD 981693 or MKC 1693.

9. The hyperstable liposome of claim 6 or 7, wherein the anti-mitotic drug is BI 2536 or Ispinesib.

10. The hyperstable liposome of any one of claims 1-9, wherein the anti-mitotic drug is BI 2536.

11. The hyperstable liposome of claim 10, wherein the anti-mitotic drug is BI 2536 or Ispinesib and the two anions are citrate and phosphate in a ratio of 1:3.

12. A liposome composition comprising the hyperstable liposome of any of claims 1-11 in an aqueous medium.

13. A pharmaceutical composition comprising the hyperstable liposome of any one of claims 1-11.

14. The pharmaceutical composition of claim 13, wherein the composition further comprises at least one pharmaceutically acceptable excipient and/or carrier.

15. Use of the hyperstable liposome of any one of claims 1-11 or the liposome composition of claim 12 for preparing a medicament for treating cancer in a subject.

16. Use of the pharmaceutical composition of claim 13 or 14 for preparing a medicament for treating cancer in a subject.

17. The hyperstable liposome of any one of claims 1-11 for use in preparing a medicament for treating cancer in a subject.

18. The hyperstable liposome of any one of claims 1-11 or the liposome composition of claim 12 or the pharmaceutical composition of claim 13 or 14 for use in treating cancer in a subject.